Abeona Therapeutics Inc. said its investigative gene therapy ABO-202 received the U.S. Food and Drug Administration's rare pediatric disease designation.
The Dallas-based biopharmaceutical company is studying the medicine for treating the infantile Batten disease, which affects the nervous system in newborns.
In February, the investigational medicine received the U.S. FDA's orphan drug designation.
